[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Trisalus Life Sciences Inc (TLSI)

Trisalus Life Sciences Inc (TLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 199,858
  • Shares Outstanding, K 61,306
  • Annual Sales, $ 45,150 K
  • Annual Income, $ -39,230 K
  • EBIT $ -28 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.56
  • Price/Sales 4.68
  • Price/Cash Flow N/A
  • Price/Book 16.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.11
  • Number of Estimates 1
  • High Estimate $-0.11
  • Low Estimate $-0.11
  • Prior Year $-0.27
  • Growth Rate Est. (year over year) +59.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.20 +48.18%
on 05/13/26
4.85 -32.78%
on 04/23/26
-1.34 (-29.13%)
since 04/22/26
3-Month
2.20 +48.18%
on 05/13/26
5.58 -41.58%
on 02/26/26
-2.19 (-40.18%)
since 02/20/26
52-Week
2.20 +48.18%
on 05/13/26
7.95 -58.99%
on 12/22/25
-2.09 (-39.07%)
since 05/22/25

Most Recent Stories

More News
TLSI ALERT: Levi & Korsinsky Investigates TriSalus Life Sciences, Inc. on Behalf of Shareholders Who Lost Money

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:...

TLSI : 3.26 (-5.51%)
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus”...

TLSI : 3.26 (-5.51%)
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI ) investors concerning the Company’s...

TLSI : 3.26 (-5.51%)
Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - May 19, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:TLSI)...

TLSI : 3.26 (-5.51%)
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud

TriSalus Life Sciences Inc. guided investors to $60-$62 million in 2026 revenue on March 5, then slashed that outlook to $54-$57 million months later

TLSI : 3.26 (-5.51%)
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (NASDAQ: TLSI ) on behalf of investors concerning...

TLSI : 3.26 (-5.51%)
Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Contact Levi & Korsinsky to Protect Your Rights

New York, New York--(Newsfile Corp. - May 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. ("TriSalus Life Sciences, Inc.") (NASDAQ:...

TLSI : 3.26 (-5.51%)
TriSalus Life Sciences Q1 Earnings Call Highlights

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed...

TLSI : 3.26 (-5.51%)
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark,...

TLSI : 3.26 (-5.51%)
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge...

TLSI : 3.26 (-5.51%)

Business Summary

TriSalus Life Sciences Inc. is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. TriSalus Life Sciences Inc., formerly known as MedTech Acquisition Corporation, is based in CHICAGO.

See More

Key Turning Points

3rd Resistance Point 3.69
2nd Resistance Point 3.60
1st Resistance Point 3.43
Last Price 3.26
1st Support Level 3.17
2nd Support Level 3.08
3rd Support Level 2.91

See More

52-Week High 7.95
Fibonacci 61.8% 5.75
Fibonacci 50% 5.07
Fibonacci 38.2% 4.40
Last Price 3.26
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.